Health
Moderna doses first patients in COVID-19 vaccine booster trial – The Science Board
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.
The new candidate, messenger RNA (mRNA)-1273.351, encodes the prefusion stabilized spike protein of the SARS-CoV-2 variant B.1.351, first identified in South Africa, and is being assessed as a booster vaccine to increase the response to emerging SARS-CoV-2 variants. The company is also investigating a second, multivalent candidate, mRNA-1273.211, that is a combination of mRNA-1273 and mRNA-1273.351.
Through a phase II clinical trial amendment, the company will enroll 60 participants previously vaccinated…
-
General14 hours ago‘We are here for you’: PM to bring help to flood zones
-
General12 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening
-
Noosa News20 hours agoStudents say new facility would be better in rural areas of Queensland
-
General11 hours agoUK PM talks US tariff response with Albanese and Meloni